REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

REQUITE consortium

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung). Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation “damage” but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.

Original languageEnglish
Pages (from-to)59-67
Number of pages9
JournalRadiotherapy and Oncology
Volume138
DOIs
Publication statusPublished - Sep 2019

Fingerprint

Multicenter Studies
Lung Neoplasms
Prostatic Neoplasms
Cohort Studies
Radiotherapy
Breast Neoplasms
Breast
Prostate
Databases
Lung
Radiation Tolerance
Biomarkers
Radiation
Dyspnea
Atrophy
Neoplasms
Genotype
Quality of Life
Prospective Studies
Lymphocytes

Keywords

  • Biomarkers
  • Breast cancer
  • Late radiotherapy side effects
  • Lung cancer
  • Prediction models
  • Prostate cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

REQUITE : A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. / REQUITE consortium.

In: Radiotherapy and Oncology, Vol. 138, 09.2019, p. 59-67.

Research output: Contribution to journalArticle

@article{d03ba7f55302451d991aa15417c412ea,
title = "REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer",
abstract = "Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. Results: The study recruited 2069 breast (99{\%} of target), 1808 prostate (86{\%}) and 561 lung (51{\%}) cancer patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥2 CTCAE toxicities are 13{\%} atrophy (breast), 3{\%} rectal bleeding (prostate) and 27{\%} dyspnoea (lung). Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation “damage” but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.",
keywords = "Biomarkers, Breast cancer, Late radiotherapy side effects, Lung cancer, Prediction models, Prostate cancer",
author = "{REQUITE consortium} and Petra Seibold and Adam Webb and Aguado-Barrera, {Miguel E.} and David Azria and Celine Bourgier and Muriel Brengues and Erik Briers and Ren{\'e}e Bultijnck and Patricia Calvo-Crespo and Ana Carballo and Ananya Choudhury and Alessandro Cicchetti and Johannes Cla{\ss}en and Elena Delmastro and Dunning, {Alison M.} and Elliott, {Rebecca M.} and Farcy-Jacquet, {Marie Pierre} and Pietro Gabriele and Elisabetta Garibaldi and Antonio G{\'o}mez-Caama{\~n}o and Sara Guti{\'e}rrez-Enr{\'i}quez and Higginson, {Daniel S.} and Kerstie Johnson and Ram{\'o}n Lobato-Busto and Meritxell Moll{\`a} and Anusha M{\"u}ller and Debbie Payne and Paula Peleteiro and Giselle Post and Tiziana Rancati and Tim Rattay and Victoria Reyes and Rosenstein, {Barry S.} and {De Ruysscher}, Dirk and {De Santis}, {Maria Carmen} and J{\"o}rg Sch{\"a}fer and Thomas Schnabel and Elena Sperk and Symonds, {R. Paul} and Hilary Stobart and Bego{\~n}a Taboada-Valladares and Talbot, {Christopher J.} and Riccardo Valdagni and Ana Vega and Liv Veldeman and Tim Ward and Christian Wei{\ss}enberger and West, {Catharine M.L.} and Jenny Chang-Claude",
year = "2019",
month = "9",
doi = "10.1016/j.radonc.2019.04.034",
language = "English",
volume = "138",
pages = "59--67",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - REQUITE

T2 - A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

AU - REQUITE consortium

AU - Seibold, Petra

AU - Webb, Adam

AU - Aguado-Barrera, Miguel E.

AU - Azria, David

AU - Bourgier, Celine

AU - Brengues, Muriel

AU - Briers, Erik

AU - Bultijnck, Renée

AU - Calvo-Crespo, Patricia

AU - Carballo, Ana

AU - Choudhury, Ananya

AU - Cicchetti, Alessandro

AU - Claßen, Johannes

AU - Delmastro, Elena

AU - Dunning, Alison M.

AU - Elliott, Rebecca M.

AU - Farcy-Jacquet, Marie Pierre

AU - Gabriele, Pietro

AU - Garibaldi, Elisabetta

AU - Gómez-Caamaño, Antonio

AU - Gutiérrez-Enríquez, Sara

AU - Higginson, Daniel S.

AU - Johnson, Kerstie

AU - Lobato-Busto, Ramón

AU - Mollà, Meritxell

AU - Müller, Anusha

AU - Payne, Debbie

AU - Peleteiro, Paula

AU - Post, Giselle

AU - Rancati, Tiziana

AU - Rattay, Tim

AU - Reyes, Victoria

AU - Rosenstein, Barry S.

AU - De Ruysscher, Dirk

AU - De Santis, Maria Carmen

AU - Schäfer, Jörg

AU - Schnabel, Thomas

AU - Sperk, Elena

AU - Symonds, R. Paul

AU - Stobart, Hilary

AU - Taboada-Valladares, Begoña

AU - Talbot, Christopher J.

AU - Valdagni, Riccardo

AU - Vega, Ana

AU - Veldeman, Liv

AU - Ward, Tim

AU - Weißenberger, Christian

AU - West, Catharine M.L.

AU - Chang-Claude, Jenny

PY - 2019/9

Y1 - 2019/9

N2 - Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung). Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation “damage” but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.

AB - Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung). Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation “damage” but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.

KW - Biomarkers

KW - Breast cancer

KW - Late radiotherapy side effects

KW - Lung cancer

KW - Prediction models

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85066086421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066086421&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2019.04.034

DO - 10.1016/j.radonc.2019.04.034

M3 - Article

C2 - 31146072

AN - SCOPUS:85066086421

VL - 138

SP - 59

EP - 67

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -